Display Settings:

Format

Send to:

Choose Destination
    Cancer Res. 2009 Oct 15;69(20):8111-9. Epub 2009 Oct 6.

    Runt-related transcription factor RUNX3 is a target of MDM2-mediated ubiquitination.

    Source

    Departments of Biochemistry, College of Medicine, Institute of Tumor Research, Chungbuk National University, Cheongju, South Korea.

    Abstract

    The p14(ARF)-MDM2-p53 pathway constitutes an effective mechanism for protecting cells from oncogenic stimuli such as activated Ras and Myc. Importantly, Ras activation induces p14(ARF) and often occurs earlier than p53 inactivation during cancer development. Here, we show that RUNX3, a tumor suppressor in various tumors including stomach, bladder, colon, and lung, is stabilized by Ras activation through the p14(ARF)-MDM2 signaling pathway. RUNX3 directly binds MDM2 through its Runt-related DNA-binding domain. MDM2 blocks RUNX3 transcriptional activity by interacting with RUNX3 through an acidic domain adjacent to the p53-binding domain of MDM2 and ubiquitinates RUNX3 on key lysine residues to mediate nuclear export and proteasomal degradation. Our data indicate that the lineage-specific tumor suppressor RUNX3 and the ubiquitous p53 protein are both principal responders of the p14(ARF)-MDM2 cell surveillance pathway that prevents pathologic consequences of abnormal oncogene activation.

    PMID:
    19808967
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC3059505
    Free PMC Article

    Images from this publication.See all images (6) Free text

    Figure 1
    Figure 3
    Figure 5
    Figure 2
    Figure 4
    Figure 6

      Supplemental Content

      Icon for HighWire Press Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk